gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin bold data xlmtm pi vaccin updat
highlight week septemb octob audent buy present
annual congress updat data phase i/ii trial gene therapi gt x-
link myotubular myopathi xlmtm updat result show first treat patient ventilator-
independ achiev signific mileston includ sit unassist rise stand walk
without assist result us posit ahead potenti bla file buy
present idweek updat result phase trial mrna vaccin human
metapneumoviru hmpv parainfluenza viru type data includ interim analysi dose
cohort random placebo-control studi healthi seroposit adult treatment well toler
antibodi titer baselin month timepoint outcom larg line prior data
us highlight progress prophylact vaccin space arbutu biopharma neutral announc would
discontinu develop lead asset oral capsid inhibitor hepat healthi subject phase
ia/ib trial develop acut hepat result compani decid suspend plan
initi combin trial subcutan rnai therapeut hepat infect sarepta therapeut
unrat announc result phase i/iia trial gt patient
age limb-girdl muscular dystrophi type efficaci readout includ reduc level biomark
creatin kinas reduct rel baselin improv function outcom includ north
assess dysferlinopathi increas point rel baselin new seriou advers event sae
report though compani note past disclosur elev liver enzym observ patient
look forward octob octob chardan annual genet medicin confer
take place new york citi featur present public privat genet medicin compani
thought leader octob american academi ophthalmolog annual meet held
san francisco california agenda includ adverum biotechnolog neutral gensight biolog neutral
meiragtx buy chardan top pick nightstar therapeut unrat compani
buy chardan top pick neutral
weekli price move vivo genet medicin aav srna mrna vivo gene edit
mrna mm vivo gene edit mm contributor buy mm qure
upcom chardan genet medicin event contact chardan rsvp
neutral reduc workforc focu resourc octob livshit
announc restructur reduc compani workforc around end
reduct enabl focu clinic develop cancer-select gt fc
compani plan present complet analysi full trial societi neuro-
oncolog sno annual meet take place novemb phoenix arizona
note septemb research complet analysi studi may indic potenti
avenu path forward specif patient subset could provid insight addit factor
pleas refer import disclosur inform regul analyst certif found page report
consid futur rhgg trial design howev given miss primari secondari endpoint
relat overal surviv durabl respons respect maintain low expect po
 fc regimen hgg absenc new inform
abu neutral downgrad neutral due discontinu develop octob naka
arbutu biopharma announc discontinu clinic develop small molecul capsid inhibitor
treatment hepat viru decis due emerg safeti concern associ acut
hepat normal healthi volunt phase ia/ib trial
believ latest setback rais question compani small molecul design capabl henc
downgrad rate buy neutral
buy increas nab titer month octob amusa
present idweek data demonstr vaccin increas neutral antibodi nab
titer hmpv baselin month post vaccin phase studi
result plan interim analysi show treatment gener well toler increas neutral
antibodi titer seroposit individu baselin month dose level
test first interim readout announc februari magnitud increas titer
similar across level note declin titer day see mainten titer
baselin posit program
us data collect highlight steadi progress across prophylact vaccin modal
model bn risk-adjust sale forecast
bold buy new xlmtm data ahead bla file octob amusa
audent therapeut announc updat posit phase i/ii data xlmtm gene therapi
updat aspiro trial data present intern annual congress
world muscl societi copenhagen find
 first patient cohort cohort ventilator-independ
 patient attain signific mileston sit unassist rais stand posit walk
 muscl biopsi show robust dose-depend transduct transcript express histolog
 without support
 new sae joint swell report patient cohort week resolv without treatment
compani expect immin complet enrol aspiro pivot dose expans cohort
vg/kg audent expect file bla europ
genet medicin news septemb octob
rhhbi unrat announc extens tender offer neutral septemb
buy announc approv ind mrna tx propion acidemia septemb
mit publish deliveri immun respons mrna vaccin septemb
unrat open manufactur facil ipsc-deriv cell therapi septemb
adap unrat present data pi trial spear t-cell patient synovi sarcoma septemb
adaptimmun present european societi medic oncolog emso congress data phase trial
patient patient best overal respons rate orr confirm
unconfirm partial respons pr best orr stabl diseas thu patient show
clinic benefit diseas control rate defin orr confirm unconfirm pr stabl diseas
patient pr confirm unconfirm confirm on-going pr
subsequ diseas progress
fatal aplast anemia previous announc report fda occur patient
tng fp unrat announc pib data therapeut vaccin hpv cancer esmo septemb
transgen present phase ib data therapeut vaccin base vaccinia vector design express
antigen vaccin test combin antibodi avelumab heavili
pre-treat patient recurr metastat hpv malign
page
durabl partial respons observ patient treat higher dose dose limit
toxic measur immun function show t-cell respons specif patient blood
day increas t-cell infiltr includ t-cell tumor microenviron increas
express tumor cell also observ
compani note therapi compar favor current treatment patient receiv line treatment
hpv-associ indic metastat diseas
next clinic readout phase ii portion trial occur
ly fp unrat announc financi result provid busi updat septemb
unrat announc appoint david boyer corpor affair offic septemb
unrat announc appoint dr cockroft svp chief medic offic septemb
molecular therapeut privat file ipo list septemb
privat file ipo list septemb
avid bioscienc privat announc appoint sarah boyc ceo octob
agtc buy announc collab otonomi unrat aav-bas gt snhl octob
unrat announc ind clear pi car-t relaps leukemia lymphoma octob
tmuniti privat announc collabor chop car-t neuroblastoma octob
privat announc ind clearanc patient mpv octob
inscripta privat announc launch benchtop platform genom engin octob
cll unrat announc agreement lonza unrat manufactur ucart octob
ethri privat collabor munster hospit studi rna-bas therapeut pcd octob
phio unrat file initi registr public issu common stock warrant octob
alpmf unrat announc invest nearli incub boston area octob
univ heidelberg publish aav-medi gene therapi transplant vasculopathi octob
privat announc board director scientif advisori board octob
unrat announc articl neuromuscular disord spinraza infant sma octob
nih publish improv lentivir vector gt hemoglobin disord octob
unrat announc leas agreement build new facil rockvil maryland octob
adap unrat announc appoint michael garon interim cfo octob
buy announc interim pi data mrna vaccin hmpv octob
nppni unrat announc nda submiss morpholino oligom viltolarsen dmd octob
dynacur privat present preclin data target aso therapeut skelet muscl octob
adicet privat announc mm seri rais advanc oncolog program octob
tenaya tx privat announc mm seri advanc cardiac diseas program octob
arcellx privat announc mm seri financ cell therapi platform octob
verv tx privat announc appoint dr andrew belling cso octob
moffitt cancer center announc launch immunotherapy-focus cro octob
unrat announc result pi/iia trial gt octob
sarepta announc result patient phase i/iia trial
receiv infus vg/kg gene therapi limb-girdl muscular dystrophi
page
rel baselin patient show improv motor function reduct creatin kinas level
day compani previous report muscl biopsi result show mean beta-sarcoglycan
compani plan test higher dose prior select appropri dose advanc clinic
nv unrat present interim data pi/ii trial gt sma type octob
compani mention report
page
select catalyst genet medicin coverag
aro-aat initi phase ii/iii studi liver diseas
lumasiran initi illuminate-c phase trial
file ind pomp diseas
initi phase i/ii clinic trial huntington diseas
initi phase ii trial /- cemiplimab cutan squamou cell carcinoma
initi phase trial /- solid tumor
initi phase i/ii trial dmd nationwid children hospit
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
provid initi data phase trial gangliosidosi
axo-lenti-pd report data cohort sunrise-pd phase ii trial
submit ind methylmalon acidemia mma
present data phase portion solid tumor trial /- nivolumab
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
top-lin phase ii data treat deb patient chronic wound
initi dose phase trial hemophilia
provid updat priorit program sjogren syndrom al wet
initi patient dose brillianc phase i/ii trial
report result phase i/ii ignit dmd trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
present preclin data new gt program fabri pomp defici
provid follow-up data piib dose-confirm studi hemb
file ind cta pomp diseas
dose patient phase studi mp
provid updat phase i/ii studi hemophilia
present top-lin data phase i/iia clinic trial wet
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
figur meiragtx replimun solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
zolgensma anticip approv eu
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
valrox submit bla pend fda feedback hemophilia
initi pivot phase trial rdeb
initi phase data patient leukocyt adhes deficiency-i lad-i
report initi phase data process fanconi anemia
suvodirsen interim data open-label extens studi dmd
initi phase studi pyruv kinas defici pkd
initi us phase ii studi fanconi anemia
initi phase i/ii trial parkinson diseas mutat
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
initi phase ib trial beta-thalassemia
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
begin patient dose phase trial
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
report initi data phase i/ii trial phenylketonuria pku
rituximab report preliminari phase cohort data r/r nhl
file ind gangliosidosi
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl neutral
figur select price movement week end oct vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm genet therapytickerratingccm ptupsideclosechang changemc mm arrowhead gene editingtickerratingccm ptupsideclosechang changemc mm logicbio pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid technolog
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan recombinet technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
ultragenyx genetx
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
